SCANCELL HLDGS ORD 0.1P (LSE:SCLP)

32.500
Today's low: 32.500
Sell SCLP
34.000
Today's high: 33.425
Buy SCLP
Last trade:
33.250
Change:
 - (-%)
Volume:
31,000
Delayed price:
16:35:21
SETSqx
GBX

SCANCELL HLDGS ORD 0.1P (SCLP.L, LSE, LSE:SCLP)

SCLP Share Performance More

52 week high52.500 20-06-2013
52 week low22.510 17-07-2013
52 week change -10.000 (-23.12%)
4 week volume5,603,927 28-03-2014

Latest newsMore

Scancell to present Phase I/II data for SCIB1

Scancell Holdings said interim data from its Immunobody (SCIB1) Phase III clinical trial in patients with Stage IIIIV melanoma will be presented at the upcoming American Association for Cancer Research annual meeting in San Diego, 5-9 April 2014. Scancell develops novel immunotherapies for cancer treatment.

Scancell to present Phase I/II data for SCIB1

Scancell to present SCIB1 at AACR

RNS Number : 0312E Scancell Holdings Plc 04 April 2014 4 April 2014 Scancell Holdings Plc (Scancell or the Company) Scancell to present SCIB1 at American Association for Cancer Research Annual Meeting Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that interim data from its Immunobody (SCIB1) Phase III clinical trial in patients with Stage IIIIV melanoma will be ...

Scancell says higher-dose SCIB1 study on track

Scancell, the developer of novel immunotherapies for cancer, has completed patient dosing with 8mg of SCIB1 ImmunoBody (SCIB1) in Part 1 of its on-going Phase 12 clinical trial in patients with Stage IIIIV melanoma. Five patients with metastatic tumours have been recruited and dosed, with no reported drug or device-related serious adverse events, Scancell said in a statement. Immunology and clinical responses in this higher dose cohort of ...

8mg Higher Dose SCIB1 Study On Track

RNS Number : 8336C Scancell Holdings Plc 21 March 2014 21 March 2014 Scancell Holdings Plc (Scancell or the Company) 8mg Higher Dose SCIB1 Study On Track Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce completion of patient dosing with 8mg of SCIB1 ImmunoBody (SCIB1) in Part 1 of its on-going Phase 12 clinical trial in patients with Stage IIIIV melanoma. ...

Scancell says patent for Moditope platform published

Scancell Holdings, the developer of novel immunotherapies for the treatment of cancer, said its application for the patent underpinning its Moditope platform has been published. When granted, this patent will protect the platform to at least 2033. The patent application, describes how the Moditope immunotherapy platform harnesses CD4+ T cells to eradicate tumours. At 8:09am: (LON:SCLP) Scancell Holdings PLC share price was +0.75p at 34.25p